Refine by
Antibiotic Tylosin On Treatment Articles & Analysis
32 news found
The Centers for Disease Control and Prevention (CDC) reports there are an estimated 450,000 cases of shigellosis, an infection caused by Shigella bacteria, in the United States each year. Unfortunately, a growing number of these infections involve drug-resistant Shigella. The four species of Shigella listed by the CDC include: Shigella sonnei (the most common species in the United States) ...
Alfa Chemistry, a recognized leader in the alkaloid industry, has expanded its offerings to include a comprehensive range of alkaloids-related natural products. This expansion underscores its commitment to providing high-quality compounds for various applications in medicine, food, and cosmetics. The suite of products now includes saccharides, flavonoids, terpenoids, phenylpropanoids, ...
Amerigo Scientific, a distributor focused on providing critical products and services to biomedical and life science communities, unveils the addition of the reliable Daptomycin ReadyMade™ Solution to its growing portfolio of innovative products to power up spectrum and microbiology applications. Daptomycin is an essential antibiotic used in the treatment of serious bacterial infections, ...
MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation for providing reliable sequencing, genotyping, microarray, and bioinformatics services. The company has launched the Phage Whole-Genome Sequencing to help discover biomarkers and develop non-antibiotic treatment methods. Phages ...
A research team in Zurich, Switzerland has presented results from an in vitro study showing that photodisinfection achieved >99.99% eradication (4-7 log10 kill) of the key pathogens in biofilms associated with implantable joint infections, with no reported regrowth. These results were presented at the recent Swiss Society for Microbiology (SSM) Annual Congress 2022 in Lausanne, Switzerland. ...
MerLion Pharmaceuticals GmbH (MerLion), a pharmaceutical company focused on the development of novel antibiotics, reported the receipt of the final meeting minutes from the U.S. Food and Drug Administration (FDA) following a successful Type C meeting with the Agency on the development of the antibiotic finafloxacin for the treatment of melioidosis, in a naturally occurring as well as a biodefense ...
Liaison Memed Bv is an immune system based protein signature test for distinguishing between bacterial and viral infections The test was developed following the licensing agreement signed with Memed as announced in September 2020 The new test is available on the Liaison Xl platforms in countries that accept CE mark and U.S. food and drug administration clearance is planned for 2022 ...
ByMeMed
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5% Unyvero results combined with antibiotic stewardship are efficient and safe in decreasing time on inappropriate ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a long-lasting colony of beneficial gut microbes, which can ...
Before Alexander Fleming discovered penicillin, another more selective antibacterial agent rose to popularity in the early 1900s: bacteriophage. In 1917, microbiologist Felix d’Herelle was tasked with identifying the cause of a dysentery outbreak impacting French troops. From his research, he noticed that Shigella bacteria was the primary culprit of this affliction. He then discovered an ...
High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo Represents most advanced clinical trial of a rationally defined bacterial consortium candidate BARDA exercises $23.8 million option to support Phase 3 clinical trial of VE303, to ...
Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI) Only gut microbiome research program with five clinical studies demonstrating consistent ...
Salvatore J. Salamone, Ph.D. received the prestigious Dr. C.E. Pippenger Award at the 2021 International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting in Rome, Italy. This award is given to individuals who have made outstanding contributions to the field of Therapeutic Drug Monitoring (TDM). TDM is a field of medical science that seeks to ensure that ...
In Patients Who Receive Ineffective Empirical Antibiotics for Blood Stream Infections (BSI), Use of AXDX Was Associated With Reduction in 30-Day Mortality Interim Data From Multicenter Study Highlight the Real-World Clinical Utility of Fast Phenotypic Antimicrobial Susceptibility Testing for BSI Across Diverse Healthcare Settings and Patient Populations Accelerate Diagnostics, Inc. ...
Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for the treatment of severe diarrhea induced by shiga-toxin (Stx) producing E. coli (STEC, leading to Hemolytic Uremic Syndrome), at the 14th Annual CRISPR 2021 meeting held June 1-10, 2021. The data presented further supports ...
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection RBX2660 Phase 3 data add to the world’s largest and most robust clinical program ever conducted in ...
MerLion Pharmaceuticals GmbH (MerLion), a biopharmaceutical company focused on research and development of novel antibiotics for the treatment of serious bacterial infections, today announced the successful completion of a growth financing round raised via a private placement to European strategic investors. The funds raised will primarily be used to finance the production and market launch of ...
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces enlightening findings from its primary market research with optometrists and ophthalmologists related to contact lens drug delivery and its proprietary pipeline of assets. Key learnings from the market ...
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper in the peer-reviewed journal Scientific Reports, describing a study into the bacterium Staphylococcus aureus (S. aureus). The paper can be accessed ...
Keiretsu Forum announced today that OtoNexus Medical Technologies was named 'Most Valued Company' at the virtual Keiretsu Forum Investor Capital Expo. Keiretsu Forum is the world's largest angel investor network with over 3,000 investors in over 50 chapters on three continents. Keiretsu Forum has invested more than $750 million into more than 1,000 companies since its inception. ...